GLP-1 agonists are very promising for the treatment of PCOS in affected women with overweight or obesity. Cree is moving ahead with her PCOS trials anyway, though shes concerned the widespread demand could complicate her larger trials expected start date, August
During the first 36 months, most patients experience rapid weight loss due to reduced appetite and slower stomach emptying
Along with numbers on the scale, risks for diabetes, kidney and heart diseases, fatty liver disorders, and cancer all appear to go down
For managing obesity and diabetes, these medications work by slowing digestion, reducing appetite, and enhancing insulin release in response to meals
They affect digestive function as part of their mechanism of action